| Age (years) | 54 ± 13 |
| Male/female | 37 (73%)/14 (27%) |
| Years since diagnosis | 2.5 ± 2.8 |
| Functional class (I/II/III, according to NYHA) | 20 (39%)/28 (55%)/3 (6%) |
| Medication |
|
| b-receptor blockers | 47 (92%) |
| Angiotensin converting enzyme inhibitors | 41 (80%) |
| Angiotensin-receptor blockers | 6 (12%) |
| Diuretics | 16 (31%) |
| Spironolactone | 1 (2%) |
| Digitalis | 10 (20%) |
| Warfarin | 17 (33%) |
| Acetosalicylic acid | 14 (27%) |
| Statins | 11 (22%) |
| Long-acting nitrates | 4 (8%) |
| Calcium-channel blockers | 1 (2%) |
| Other antiarrhythmic drug | 1 (2%) |
| BMI (kg/m²) | 28 ± 5 |
| SBP (mmHg) | 129 ± 22 |
| DBP (mmHg) | 82 ± 12 |
| LBBB | 20 (39%) |
| Ergospirometry |
|
| Wlast4 (W) | 123 ± 51 |
| VO2max (ml/min/kg) | 21.5 ± 8.5 |
| Gated SPECT |
|
| LVEDV (ml) | 172 ± 90 |
| LVESV (ml) | 126 ± 88 |
| LVEF (%) | 30 ± 12 |
| Catheterization |
|
| LVEDP (mmHg) | 15 ± 8 |
| PAPm (mmHg) | 18 ± 7 |
| PCWPm (mmHg) | 10 ± 6 |
| CI (l/min/m²) | 2.9 ± 1.9 |
| Clinical chemistry |
|
| NE (nmol/l) | 2.3 ± 1.2 |
| NT-proBNP (pmol/l) | 179 ± 183 |
| hs-CRP (mg/l) | 2.8 ± 3.4 |
| IL-6 (pg/ml) | 2.4 ± 1.6 |
| Echocardiography |
|
| LVEDD (mm) | 65 ± 9 |
| LVESD (mm) | 52 ± 10 |
| LVEF (%) | 38 ± 9 |
| E/A-ratio | 1.0 ± 0.6 |